For over a decade global pharmaceutical and biotech companies have utilized our expertise to ensure rapid
progress in late phase clinical development at some of the most optimum costs worldwide. Phase III constitutes a
large part of our business and are reflective of our ability to provide the major patient load to global studies.
Over years we have designed a process that is proactive, creative and collaborative to balance your scientific and
commercialization objectives with the highest degree of regulatory compliance.
A high rate of operational success is assured through an integrated late phase study management team, consisting
of experienced, pharmaceutical industry and clinical development professionals.
SIRO has extensive experience of conducting Phase III and IV studies of all sizes for global regulatory
submissions. We have worked collaboratively with other CROs as a part of global studies to ensure that our
clients get the best of our strengths.
Our experts can work with you in the design phase and provide strategies to help you reach the market
Our experience includes
- Trials to expand safety and support ongoing filing
- Registration trials to expand indication
- Cross-over trial designs